Immunomodulation by imiquimod in patients with high-risk primary melanoma - Wikidata - wikimedia - TriplyDB

Immunomodulation by imiquimod in patients with high-risk primary melanoma

Immunomodulation by imiquimod in patients with high-risk primary melanoma

http://www.wikidata.org/entity/Q35590166

about

Use of imiquimod for residual acral melanoma Classification of current anticancer immunotherapies Dual roles of TLR7 in the lung cancer microenvironment.Treatment of in-transit melanoma with intralesional bacillus Calmette-Guérin (BCG) and topical imiquimod 5% cream: a report of 3 cases.Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma.pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation.Topical treatment of recurrent vaginal melanoma in situ with imiquimod: A case report.Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.Modes of action of TLR7 agonists in cancer therapy.Anti-tumor Activity of Toll-Like Receptor 7 Agonists.Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.Core/shell protein-reactive nanogels via a combination of RAFT polymerization and vinyl sulfone postmodification.Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma.Trial Watch: Toll-like receptor agonists for cancer therapy.Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions.Intratumoral immunotherapy: using the tumor as the remedy.Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.

P2860

Q34130648-9FD12159-56C6-4F2A-88D5-49F77299E61D Q35149637-31B9936D-F2DF-415F-B4DE-83A70E855E99 Q35506268-2C96F726-D46E-423E-B7FA-2C2B89127202 Q36322376-C7E4CC26-2A3A-4C7D-ABC2-6F420EEAB778 Q36476394-EA816D25-4B39-4A9E-9FE6-F896B5E8501F Q36632306-A3A93B54-0E63-4397-8159-DB95D3E1B0F9 Q36908347-18ADED98-FA79-4405-8B04-7B6218176193 Q37126646-E80D7BD5-97A8-4685-A927-71D877AEC994 Q37387579-AD1CF076-D0A5-49D1-AE71-2457FA8B52AD Q37527772-F3C3188E-560B-4E2C-B4BE-1C8D227845C9 Q38124064-AEF0B8CB-87EF-42DC-9F34-6046D1C3A6F3 Q38271879-17F9A884-F9EB-4C17-B774-16FB20073FD2 Q39377049-2C174D70-469A-496B-8D25-88ABB51C87BD Q41349651-454775FD-43DB-479A-949D-0A9624BBDC5B Q41654079-559FA1FE-667F-4E82-9EE4-BC225EAC609E Q42214222-911ABDC9-56FA-4A62-AFD0-ABBA87FFE407 Q42969291-3485CCE7-8D28-49D9-8C6A-4063871CAF0A Q46232926-C029E298-3C5E-48CF-93C3-42752B473328 Q47281370-2BE4B573-A657-407E-9463-B0CF5215259D Q52597538-5795D7C0-553F-4EAD-B46E-65152A2D5294

P2860

Immunomodulation by imiquimod in patients with high-risk primary melanoma

http://www.wikidata.org/entity/Q35590166

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Immunomodulation by imiquimod in patients with high-risk primary melanoma

@ast

Immunomodulation by imiquimod in patients with high-risk primary melanoma

@en

type

label

Immunomodulation by imiquimod in patients with high-risk primary melanoma

@ast

Immunomodulation by imiquimod in patients with high-risk primary melanoma

@en

prefLabel

Immunomodulation by imiquimod in patients with high-risk primary melanoma

@ast

Immunomodulation by imiquimod in patients with high-risk primary melanoma

@en

P1433

Q35590166-D7D4B7D5-7578-40FD-83DF-5368C59CFEDC

P1476

Q35590166-F59D8FFD-19E3-4206-9B0D-437142716BA8

P2093

Q35590166-23B1620E-BE30-4FD3-B72E-80B0F55C4758

Q35590166-31B346B5-4E36-4BF7-8319-23B93A2ACDA4

Q35590166-3D94E373-7DB6-47A5-9E00-5C583EB2B087

Q35590166-50CACEF8-A8D8-4EC3-8750-A26B081F22F3

Q35590166-55A5C847-19D0-44D6-9139-53D517FD1810

Q35590166-5A318F6B-4D03-4BB6-AD3A-EC8913ECA84F

Q35590166-641A6157-21E5-47C3-A7A5-64CCA414C53C

Q35590166-64C10C18-C57A-4FD1-A60D-3CBE49C77A04

Q35590166-8BBE85D8-FB2F-43DC-B01E-4763B9B70DD7

Q35590166-9937C4A3-6374-4DA7-B6A6-25576C3D479B

P2860

Q35590166-01FFC4FC-9C9A-4415-B38D-580DC77C9F05

Q35590166-0B971101-BBED-4A44-96BE-1EC826972E79

Q35590166-109267EC-0EB2-4082-8036-CF3634F3CB27

Q35590166-150E119D-4685-42F3-A995-22CAC9D8BF7B

Q35590166-2409EFB1-6756-4C84-B465-8E6142DFF26F

Q35590166-32EA433B-6235-4AB1-9576-F8440D5C7193

Q35590166-3BBBEBA3-8790-4769-839F-37405DE92877

Q35590166-3D3A5F2F-3AAC-4D22-BF4D-19583147B09E

Q35590166-43A96C33-5983-42A8-AC59-C2EAC7528E72

Q35590166-47225B93-0DDD-4089-A865-2C6816253365

P2888

Q35590166-66A09338-20C0-461E-877A-DC8F3CD83003

P304

Q35590166-2405F18C-E2DF-47F1-92A9-7B473F5E38CF

P31

Q35590166-C5320CF7-FEF2-4685-982A-07F98D3BA146

P356

Q35590166-58B75C1C-09BE-453E-82F2-2075607E56A5

P407

Q35590166-94B1C897-41AF-431E-87B3-B6CE72706A5C

P433

Q35590166-5504A51A-F25C-4256-806C-172DBFD2907B

P478

Q35590166-2DA87405-F4C3-4F31-86C1-416091A82420

P577

Q35590166-ECD0056A-CB06-4AB8-A516-DC721C6345D7

P5875

Q35590166-11BB3E9D-14E9-48C7-AF8B-6EFADBB1DB76

P698

Q35590166-7AAEA54C-2D8B-4A7F-A183-639BDBE656AD

P932

Q35590166-E97B8DBD-E017-41D2-AF2C-EB8219E17E12

P356

P1433

Journal of Investigative Dermatology

P1476

Immunomodulation by imiquimod in patients with high-risk primary melanoma

@en

P2093

Antoni Ribas

http://www.w3.org/2001/XMLSchema#string

Begonya Comin-Anduix

http://www.w3.org/2001/XMLSchema#string

Christine Dauphine

http://www.w3.org/2001/XMLSchema#string

Diana K Lee

http://www.w3.org/2001/XMLSchema#string

Hernan I Vargas

http://www.w3.org/2001/XMLSchema#string

Hong Nguyen

http://www.w3.org/2001/XMLSchema#string

Jacquelyn Haskell

http://www.w3.org/2001/XMLSchema#string

James S Economou

http://www.w3.org/2001/XMLSchema#string

Jason J Bentow

http://www.w3.org/2001/XMLSchema#string

Kevin W Bruhn

http://www.w3.org/2001/XMLSchema#string

P2860

TLR signaling pathways

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

Imiquimod in the treatment of lentigo maligna.

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential.

Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

Treatment of lentigo maligna with imiquimod before staged excision.

Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.

P2888

P304

163-169

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JID.2011.247

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51579281

http://www.w3.org/2001/XMLSchema#string

P698

21850019

http://www.w3.org/2001/XMLSchema#string

P932

3229834

http://www.w3.org/2001/XMLSchema#string